NCT04542902

Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma

Status unknown NA Last updated 9 September 2020

What this trial tests

NA trial testing Dermatophagoides pteronyssinus allergen in Allergic Asthma in 80 participants. Status unknown.

Timeline

1 October 2020

Primary endpoint
1 October 2023

1 October 2023

Quick facts

Lead sponsor	Lithuanian University of Health Sciences
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	80
Start date	1 October 2020
Primary completion	1 October 2023
Estimated completion	1 October 2023
Sites	1 location across Lithuania

Drugs / interventions tested

• Dermatophagoides pteronyssinus allergen — full drug profile →
• Blood sampling — full drug profile →
• Bronchial challenge with allergen

Conditions studied

• Allergic Asthma — all drugs for Allergic Asthma →
• Severe Eosinophilic Asthma — all drugs for Severe Eosinophilic Asthma →

Sponsor

Lithuanian University of Health Sciences

Who can join

Adults 18 to 70, any sex, with Allergic Asthma or Severe Eosinophilic Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic airway inflammation rich in eosinophils is an important feature seen in asthma. Airway and blood eosinophilia is associated with increased rates of asthma exacerbations and more intense treatment.

Recently, the existence of two distinct eosinophils subtypes was revealed-lung-resident eosinophils (rEOS), which maturate independently to interleukin (IL) 5, with the primary function to maintain tissue homeostasis, and inflammatory eosinophils (iEOS), which mature in IL-5-dependent manner and are mainly involved in immune responses. Eosinophils' effect on the airway remodeling in asthma depends not only on the activity but also by their viable number in the lungs. Blood iEOS infiltrate the airways mainly after the environmental stimulus like allergen and leave the airways with bronchial secretions. However, rEOS reside lung tissue for their entire lifetime regulating local immunity. Blood rEOS and iEOS ratio alters in asthma, compared with healthy controls. It is known that the predominant eosinophils subtype in allergic asthma are iEOS, while rEOS are basic subtype in severe eosinophilic asthma patients, moreover, they are different in adhesive properties and survivability as well. Distinct biological properties allows to speculate about their different functions in asthma, however, there are still little information. Data about differently expressed microRNA (miRNA) profiles in eosinophils in asthma suggests, that eosinophils subtypes can be distinct in non-coding RNA (ncRNA) - microRNA (miRNA), piwi-interacting RNA (piRNA) and long non-coding RNA (IncRNA) profiles that could describe their role in asthma pathogenesis and act as biomarkers to discern asthma phenotypes.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Exosomes─Nature's Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics.
   Tenchov R, Sasso JM, Wang X, Liaw WS, et al · · 2022 · cited 336× · PMID 36354238 · DOI 10.1021/acsnano.2c08774
2. Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
   Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
3. Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine.
   Sharma A, Yadav A, Nandy A, Ghatak S. · · 2024 · cited 40× · PMID 38931833 · DOI 10.3390/pharmaceutics16060709
4. The Role of Non-Immune Cell-Derived Extracellular Vesicles in Allergy.
   Hovhannisyan L, Czechowska E, Gutowska-Owsiak D. · · 2021 · cited 17× · PMID 34489951 · DOI 10.3389/fimmu.2021.702381
5. Blood Inflammatory-like and Lung Resident-like Eosinophils Affect Migration of Airway Smooth Muscle Cells and Their ECM-Related Proliferation in Asthma.
   Rimkunas A, Januskevicius A, Vasyle E, Palacionyte J, et al · · 2023 · cited 9× · PMID 36834879 · DOI 10.3390/ijms24043469
6. Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma.
   Palacionyte J, Januskevicius A, Vasyle E, Rimkunas A, et al · · 2024 · cited 6× · PMID 39001236 · DOI 10.3390/diagnostics14131345
7. Novel Serum Biomarkers for Patients with Allergic Asthma Phenotype.
   Palacionyte J, Januskevicius A, Vasyle E, Rimkunas A, et al · · 2024 · cited 6× · PMID 38275403 · DOI 10.3390/biomedicines12010232
8. IL-5 and GM-CSF, but Not IL-3, Promote the Proliferative Properties of Inflammatory-like and Lung Resident-like Eosinophils in the Blood of Asthma Patients.
   Palacionyte J, Januskevicius A, Vasyle E, Rimkunas A, et al · · 2022 · cited 6× · PMID 36497064 · DOI 10.3390/cells11233804